Study #2025-0339
CD4CAR T cell therapy for AML
MD Anderson Study Status
Enrolling
Treatment Agent
CD4CAR
Description
This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in patients with relapsed or refractory AML. The study will evaluate safety in this patient population and also the presence of efficacy signal described by elimination of residual disease to qualify patients for stem cell transplant.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop UT MD Anderson
Show your support for our mission through branded merchandise.?